Nassir Marrouche, MD
Director of Cardiac Electrophysiology Laboratories
University of Utah Health Sciences Center
University of Utah Health Sciences Center
Member of the Healthcare Council
Nassir Marrouche, MD, is the Director of Cardiac Electrophysiology Laboratories and the Atrial Fibrillation Program at University of Utah Health Sciences Center. Previously, Dr. Marrouche was a Cardiologist in the Division of Pacing and Electrophysiology at Cleveland Clinic, Ohio. He is involved in multiple experimental and human research projects on invasive treatment of atrial fibrillation. Dr. Marrouche is also researching the development of a new bi-ventricular pacing device for the treatment of heart failure. (This is me - Update Profile)
| 2005 - present | Director of Cardiac Electrophysiology Laboratories University of Utah Health Sciences Center |
|---|---|
| 2003 - 2005 | Cardiologist The Cleveland Clinic Foundation |
GLG Study Groups with Nassir Marrouche, MD(?)
GLG NewsSM Analyses by Nassir Marrouche, MD(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
A new drug that would change the way we treat Atrial Fibrillation! | 05-20-2008
Analysis of:
Landmark ATHENA Study findings with dronedarone presented during the annual Heart Rhythm meeting in San Francisco | www.medscape.com
Author:
Nassir Marrouche, MD,
Director of Cardiac Electrophysiology Laboratories,
University of Utah Health Sciences Center
Atrial fibrillation management. New anti-arrhythmic medication.
GLG InstituteSM Seminars with Nassir Marrouche, MD(?)
Nassir Marrouche, MD has not participated in any GLGi Seminars.
View all GLG InstituteSM Seminars in Healthcare
View all GLG InstituteSM Seminars in Healthcare
Request a project with Nassir Marrouche, MD
Note: GLG Experts do not provide personal medical advice, diagnosis or treatment through this site.
GLG's 750+ Clients Include:
40 of the leading 50
global mutual funds
global mutual funds
15 of the leading 20
global banks
global banks
8 of the leading 10
private equity firms
private equity firms
90%+ client subscription renewal rate

